Our findings indicate that plasma IGFBP2 was elevated to the greatest extent in PDAC patients with either lymph node involvement or distant metastasis and that this elevation was associated with shorter overall survival of these patients that supports similar findings in other cancers, such as ovarian cancer [17], colorectal cancer [18], and prostate cancer [19]. This evidence concerns the gene IGFBP2 and prostate cancer.